Biomed Industries, Inc.
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome
- Conditions
- Rett Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Biomed Industries, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT06849973
- Locations
- 🇺🇸
Biomed Testing Facility # BIO-04-92093, La Jolla, California, United States
🇺🇸Biomed Testing Facility # BIO-03-90095, Los Angeles, California, United States
🇺🇸Biomed Testing Facility # BIO-02-95817, Sacramento, California, United States
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
- Conditions
- Rett Syndrome
- Interventions
- Drug: BionetideDrug: Placebo
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Biomed Industries, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06840496
- Locations
- 🇺🇸
Biomed Testing Facility # BIO-01-85012, Phoenix, Arizona, United States
🇺🇸Biomed Testing Facility # BIO-05-92093, La Jolla, California, United States
🇺🇸Biomed Testing Facility # BIO-04-90095, Los Angeles, California, United States
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
- Conditions
- Obesity and Overweight
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Biomed Industries, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06732245
- Locations
- 🇺🇸
Biomed Research Unit #90067-102, Los Angeles, California, United States
🇺🇸Biomed Research Unit # 92121-103, San Diego, California, United States
🇺🇸Biomed Research Unit # 94104-101, San Francisco, California, United States
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
- Conditions
- Overweight or ObesityType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Biomed Industries, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT06615700
- Locations
- 🇦🇺
Biomed Industries Pty Limited- Clinical Testing Site 1, Camperdown, New South Wales, Australia
🇦🇺Biomed Industries, Pty Limited Testing Site 2, Parkville, Victoria, Australia
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
- Conditions
- Body Weight ChangesBody WeightObesityWeight Loss
- Interventions
- Drug: NA-931, dose 1, daily and orallyDrug: NA-931 dose 3, daily and orallyDrug: NA-931, dose2, daily and orallyDrug: NA-931 dose 4, daily and orally
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Biomed Industries, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT06564753
- Locations
- 🇦🇺
Biomed Investigational Site, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- Next